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Abstract: Overexpression of squamous cell carcinoma antigen 1 (SCCA1) in hepatitis G2 
(HepG2) and Chinese hamster ovary cells can increase hepatitis B virus (HBV) binding capacity 
by interacting with the preS1 domain of the HBV surface antigen. However, the magnitude of 
increase in binding capacity was higher by several orders in the former, indicating the existence 
of additional factor(s) produced by HepG2 cells, which facilitates HBV attachment. Ferritin 
light chain (FTL) was identified as the sole high hit candidate by screening human liver cDNA 
library using a bacterial two-hybrid system with either preS or SCCA1 as the bait. Subsequent 
in vitro protein–protein interaction assays confirmed the binding activity of FTL to both preS 
and SCCA1, as well as the formation of triple complex preS-FTL-SCCA1, and narrowed down 
the binding sites on FTL. In vitro overexpression of FTL could further enhance HBV attachment 
in both HepG2 and Chinese hamster ovary cells, which were already overexpressing SCCA1. 
Importantly, in vivo co-expression of human FTL and SCCA1 in mouse liver by means of tail-
vein hydrodynamic injection increased serum levels of HBV surface antigen transiently 24 hours 
post challenge with HBV-positive human sera, and a large amount of HBV core antigen-positive 
hepatocytes around blood vessels could be identified by immunohistochemical staining 48 hours 
post challenge. The data strongly suggest that FTL and SCCA1 may serve as coreceptors in 
HBV cellular attachment and virus entry into hepatocytes.
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Introduction
Hepatitis B virus (HBV) is a human hepadnavirus that causes acute and chronic 
hepatitis and hepatocellular carcinoma.1 HBV infection is considered to be initiated 
by specific binding of viral envelope proteins to cell membrane structures. Its surface 
protein antigens (HBsAg) are comprised of three carboxyl-co-terminal HB proteins.2 
The large surface protein (LHBs) consists of preS1, preS2, and S domains (SHBs), 
while the middle surface protein consists of the latter two domains. PreS1 domain 
has a varying length from 109 to 120 amino acids dependent on viral subtypes, 
while preS2 is a small domain with only 55 amino acids.3 Previous studies have 
suggested a direct involvement of the preS domains (preS1 + preS2) of the LHBs in 
assisting viral attachment to hepatocytes.4,5 The attachment site of LHBs has been 
functionally narrowed down to amino acids 21–47 of preS1 by employing synthetic 
peptides.6,7
Several candidates of hepatocyte membrane receptors for HBsAg have been 
reported, including a membrane receptor for middle surface proteins associated with 
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polymerized human serum albumin,8 endonexin II (EII) as 
a specific SHBs binding protein,9 and a sialoglycoprotein 
as a receptor for SHB binding in the uptake of HBV .10,11 
However, there is little direct evidence that the interaction 
of HBV with those receptors could result in viral infections. 
Recently, a 44 kDa protein has been isolated by affinity 
chromatography using a tetravalent derivative of the preS1 
(21–47) sequence, specifically from detergent-solubilized 
plasma membranes of the human hepatocarcinoma cell 
line HepG2.12 Sequence analysis identified this protein as 
the human squamous cell carcinoma antigen 1 (SCCA1), 
a serine protease inhibitor.13 HBV attachment and internal-
ization in human hepatocytes was prohibited by external 
recombinant SCCA1, and the prohibition could be recov-
ered by antibodies against recombinant SCCA1 in a dose-
dependent manner. Overexpression of  SCCA1 increased 
HBV binding capacity both in HepG2 cells and in Chinese 
hamster ovary (CHO) cells; however, the increase in HBV 
binding was higher by several orders of magnitude in the 
former.12 This observation implies that additional factor(s) 
of HepG2 cells could facilitate HBV attachment, and may 
directly interact with both the cellular SCCA1 and the viral 
preS domain.
This study aimed to identify such cofactor(s) of SCCA1 
for HBV binding. We screened a human liver cDNA library 
on a bacterial two hybrid system by using both preS and 
SCCA1 as baits. Ferritin light chain (FTL) was found as a 
positive match and was further characterized both in vitro 
and in vivo.
Materials and methods
Bacterial two hybrid screening
BacterioMatchTM (Stratagene, Santa Clara, CA) was used 
for two hybrid screening according to the manufacturer’s 
instructions. DNA fragments encoding preS (preS1 + 
preS2) and SCCA1 were cloned into the EcoRI/BamHI 
and NotI/XhoI sites of the bait plasmid pBT, respectively. 
Human liver cell cDNA library in the target plasmid 
pTRG was purchased from Stratagene (catalog #240065). 
The pBT constructs and the pTRG library plasmids were 
cotransformed into Escherichia coli XL1-Blue MRF′ 
for protein–protein interaction positive clones screening 
on LB-CTCK plates (LB agar plates supplemented with 
300 µg/mL carbenicillin, 15 µg/mL tetracycline, 34 µg/
mL chloramphenicol, and 50 µg/mL kanamycin) at 30°C 
for 24 hours. X-gal at a final concentration of 80 µg/mL 
was used for a second round of screening. For confirmation 
of the interaction between preS1 and SCCA1, the DNA 
sequence of SCCA1 was ligated into the pTRG plasmid 
with NotI/XhoI sites.
Protein–protein interaction assay
For the in vitro protein–protein interaction study, fusion 
proteins of preS, FTL, and SCCA1 with glutathione-S-
transferase (GST)-tag, maltose binding protein (MBP)-tag, 
and histidine (His)-tag were expressed in E. coli through 
pGEX-4T-1 (carrying GST-tag, Amersham Biosciences, 
Amersham, UK), pMal-c2x (carrying MBP-tag, New 
England Biolabs, Ipswich, MA), and pET-28a (carrying 
His-tag, Merck, Darmstadt, Germany), respectively. The 
corresponding fusion proteins were purified by affinity 
chromatography with Glutathione Sepharose™ 4B (GE 
Healthcare, Little Chalfont, UK), amylose resin (New England 
Biolabs), and Chelating Sepharose™ (GE Healthcare), 
respectively, and were quantified with the bicinchoninic 
acid protein assay kit (Pierce, Rockford, IL). For a typical 
pulldown assay, 10 µg of a GST-tagged fusion protein was 
mixed with 10 µg of a MBP-tagged fusion protein and 20 µL 
of Glutathione Sepharose 4B or amylose beads in 1 mL 
phosphate-buffered saline (PBS, pH 7.0) containing 0.02% 
Tween 20. The mixture was incubated for 2 hours at 4°C 
with gentle rotation on a rotating wheel, and the beads were 
washed thoroughly with PBS containing 0.03% Tween 20 
three times (40 minutes each time) at room temperature. The 
bound proteins were dissolved by sample buffer for SDS-
PAGE and subjected to Western blotting assay by anti-MBP 
monoclonal antibody (NeoMarkers, Fremont, CA), or anti-
GST polyclonal antibodies (Shenergy Biocolor, Shanghai, 
China), or anti-His-tag polyclonal antibodies (Santa Cruz 
Biotechnology, Santa Cruz, CA).
For the in vivo immune precipitation study, fusion pro-
teins of preS, FTL, and SCCA1 with His-tag and HA-tag 
were expressed in HepG2 cells through pEGFP-N2 (without 
green fluorescent protein) and pCMV. Following typical 
immunoprecipitation assay methods, after the precipitation 
by the His-tag antibody, the bound proteins were inspected 
by anti-HA-tag antibody (Beyotime, Jiangsu, China).
Cellular attachment experiment
Infectious HBV patient serum with HBsAg- and HBeAg-
positive serology was obtained under informed consent from 
a chronically infected patient accommodated in Shanghai 
HuaDong Hospital, China. The HBV titer of this sample was 
determined to be 6.1 ± 0.2 × 106 genome equivalents/mL 
by real time polymerase chain reaction. For the attachment 
experiment, HepG2 and CHO cells cultured in 24-well   tissue 
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culture plates with Dulbecco’s Modified Eagle Medium 
containing 10% fetal calf serum, were transfected with 
pcDNA3.1-based expression vectors pcDNA3.1-SCCA1 or 
pcDNA3.1-FTL, or both of them, for 24 hours. Then 100 µL 
of HBV patient serum was added to each well, and incubated 
for 30 minutes for attachment. The cells were washed twice 
with 0.1% Tween 20-containing PBS and twice with PBS 
alone, and then lysed with 200 µL radio immunoprecipitation 
assay buffer (50 mM Tris-Cl pH 7.4 + 150 mM NaCl + 1% 
NP-40 detergent + 0.25% sodium deoxycholate + 1 mM 
phenylmethylsulfonyl fluoride) at 4°C. HBsAg dissolved 
in 100 µL radio immunoprecipitation assay buffer was 
quantified by enzyme-linked immunosorbent assay (Kehua 
  Bio-Engineering, Shanghai, China). The attachment 
  experiment was repeated three times.
In vivo overexpression of human  
FTL and SCCA1 in mouse liver  
and HBV infection assay
Six to eight-week-old male mice weighing 18–20 g were used 
for the experiment. Pure plasmid DNA (20 µg) in 2 mL Ringer’s 
buffer (147 mM NaCl + 4 mM KCl + 1.13 mM CaCl2) was 
injected into mouse tail vein over 5 seconds at a constant speed. 
This high pressure injection (hydrodynamic injection) delivers 
the injected material specifically into liver cells of the mice.14,15 
For the HBV challenge, 10 µL of human serum from HBV-
infected patients (HBV genome equivalents 6.1 ± 0.2 × 106/mL 
as determined by real-time polymerase chain reaction) was 
injected into the mouse tail vein to imitate virus infection 
24 hours post hydrodynamic injection.16 Determination of 
HBsAg in serum by enzyme-linked   immunosorbent assay, 
as well as immunohistochemical staining of liver tissues 
against HBV core antigen (HBcAg), were carried out at 
indicated time points post HBV challenge.
Results
Identification of FTL  
by two hybrid screening
To search for factors that may interact with both preS and 
SCCA1, a human liver cDNA library was subjected to bacte-
rial two hybrid screening, using preS or SCCA1 as bait. After 
two rounds of screening, 101 positive transformants were 
obtained with preS as bait, and 91 positives were derived with 
SCCA1 as bait. To our surprise, sequence analysis showed 
FTL was the only gene overlapped by both groups, with 
eight hits in preS screening and six hits in SCCA1 screen-
ing, respectively.
In vitro and in vivo validation  
of interaction of FTL with preS  
and SCCA1
To examine the interactions between FTL, preS, and 
SCCA1 in vitro, we prepared recombinant proteins tagged 
with either GST or MBP epitope to carry out pulldown 
assays. Using MBP-preS as bait, fusion protein GST-FTL 
was detected in the eluate whereas GST protein was not, 
indicating the binding of FTL to preS through FTL/preS 
interaction. Similarly, pulldown assay by using MBP-SCCA1 
as bait confirmed the interaction between FTL and SCCA1 
(Figure 1). We also performed Glutathione Sepharose beads-
based pulldown assay and similar results were achieved 
(data not shown). Furthermore, when HA-tagged preS and 
SCCA1 were coexpressed with His-tagged FTL protein in 
HepG2 cells, both tagged preS and SCCA1 were detected 
in the immunoprecipitation assay by anti-His-tag antibody. 
These results, combined with two hybrid screening confirmed 
physical binding between these three proteins.
Characterization of interactive regions 
on hFTL with preS and hSCCA1
While SCCA1 was previously characterized as a preS-
binding protein,12 how FTL binds to preS or SCCA1 was not 
determined. The three-dimensional structure of FTL contains 
five α helices, noted as A, B, C, D, and E, respectively. 
We prepared recombinant GST-tagged mutant fusion proteins, 
each with a deletion of one of the five helices. GST pulldown 
assay revealed that the binding motif of FTL to preS was 
located at α-helix A (Figure 2A), because deletion of helix A 
led to complete loss of binding activity of FTL to preS, whereas 
deletion of the other four helices did not affect interaction at 
all. In the case of SCCA1, deletion of helix A did not affect 
the binding activity of FTL to SCCA1, but deletion of any of 
the other four helices abolished binding activity. These results 
suggested differential structural dependence of FTL binding to 
preS1 and SCCA1, manifested as, if not oversimplified, FTL 
binding to preS via helix A, and binding to SCCA1 through the 
other four helices. By this way, FTL, preS, and SCCA1 may 
interact with each other to form a heterogeneous complex.
To determine the binding motif on preS2 to FTL, we 
prepared full length and truncated preS2 protein tagged with 
MBP. Pulldown experiments showed that deletion of eleven 
amino acids at the N-terminal end of preS2 disrupted interac-
tion between preS2 and FTL, whereas addition of N-terminal 
eleven amino acids of preS2 restored MBP binding activity 
to FTL (Figure 2B).
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Figure 1 (A) Western blot of preS-pulldowned proteins; (B) Western blot of SCCA1-pulldowned proteins; (C) Western blot of FTL-pulldowned proteins. For A, MBP-preS 
was pre-incubated with either GST-FTL or GST before mixing with amylose beads; for B, MBP-SCCA1 was pre-incubated with either GST-FTL or GST before mixing with 
amylose beads; for C, HA-tagged preS and SCCA1 were coexpressed with His-tagged FTL protein in HepG2 cells before immunoprecipitation by anti-His-tag antibody.
Abbreviations: MBP, maltose binding protein; GST, glutathione-S-transferase; FTL, ferritin light chain; SCCA1, squamous cell carcinoma antigen 1.
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Figure 2 (A) Determination of regions on FTL for interaction with preS and SCCA1. GST-tagged FTL deletion mutant proteins, each with deletion of one of the five 
α-helices (a to e), were allowed to bind to MBP-preS and His-SCCA1, and absorbed with Gutathione–SepharoseTM beads. Proteins absorbed on Glutathione–Sepharose 
beads were subjected to Western blotting with anti-MBP antibody (detecting MBP-preS, upper), or with His-tag antisera (detecting His-SCCA1, down). (B) Verification of 
FTL-binding activity of N-terminal 1-11 amino acids of preS2. For the upper, pulldown assay was done by mixing GST-FTL with MBP-preS2 (lane 1) or MBP-preS2∆ (1-11) 
(deletion of N-terminal 1-11 amino acids of preS2, lane 2), and the proteins recovered by Glutathione–Sepharose beads were subjected to Western blot with anti-MBP 
antibody. For the down, pulldown assay was done by mixing GST-FTL with MBP (lane 1) or MBP-peptide (1-11) (MBP with the peptide of 11 amino acids from N-terminus 
of preS2, lane2), and the proteins recovered by Glutathione-Sepharose beads were subjected to Western blot with anti-MBP antibody.
Abbreviations: FTL, ferritin light chain; MBP, maltose binding protein; SCCA1, squamous cell carcinoma antigen 1; GST, glutathione-S-transferase.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
830
Hao et alInternational Journal of Nanomedicine 2012:7
O
D
4
5
0
 
HepG2 
1234 12 34
CHO
0.8
0.6
0.4
0.2
0
Figure 3 Effect of overexpression of SCCA1, FTL on HBV attachment in HepG2 
and CHO cells. Cells were transfected with pcDNA3.1 (column 1), pcDNA3.1-
SCCA1 (column 2), pcDNA3.1-FTL (column 3), or both pcDNA3.1-SCCA1 and 
pcDNA3.1-FTL (column 4). HBsAg dissolved in RIPA buffer was measured by ELISA 
assay to quantify the HBV attachment experiment.
Abbreviations: CHO, Chinese hamster ovary; SCCA1, squamous cell carcinoma 
antigen 1; FTL, ferritin light chain; HBV, hepatitis B virus; HBsAg, hepatitis B virus 
surface protein antigens; RIPA, radio immunoprecipitation assay; ELISA, enzyme-
linked immunosorbent assay.
Coexpression of hFTL and hSCCA1 
in HepG2 cells enhances HBV cellular 
attachment
To test whether FTL works as a coreceptor for attachment of 
HBV on hepatocytes, FTL and SCCA1 were overexpressed in 
HepG2 cells and viral attachment was measured. As shown in 
Figure 3, overexpression of SCCA1 in HepG2 enhanced the 
absorption of HBV significantly, and a further increase was 
observed when SCCA1 and FTL were coexpressed. However, 
overexpression of FTL alone showed a remarkable decrease 
in HBV attachment. Similar data were observed in CHO cells. 
This phenomenon may be attributed to secreted FTL in culture 
media which saturated both the binding sites of SCCA1 in 
cell surface and of preS2 in HBV , by which it blocked the 
attachment of HBV to HepG2 cells. We tested this hypothesis 
by adding recombinant human FTL to culture media, and it 
resulted in reduced attachment of HBV to HepG2 cells as well 
(data not shown), which is in support of this idea.
Coexpression of hFTL and hSCCA1  
in mouse liver enhances HBV infection
To examine if FTL does play a role as a coreceptor of SCCA1 
to mediate HBV , human FTL and SCCA1 were expressed 
in mouse liver using a hydrodynamic injection approach.14,15 
Mice were injected with a different combination of plasmids 
to express hFTL, hSCCA1, or both, and a single dose of HBV 
challenge was administrated 24 hours post hydrodynamic 
injection. The serum level of HBsAg was measured 48 hours 
post virus challenge as a readout of virus infection. As shown 
in Figure 4A, the serum level of HBsAg in mice overexpress-
ing hFTL and hSCCA1 showed a remarkable increase in 
comparison with the other three groups. Since the increase of 
serum HBsAg compared to control is likely due to increased 
synthesis of HBsAg in HBV-infected hepatocytes, this result 
implied HBV infection and replication in these mice. To con-
firm this speculation, liver tissues were dissected for HBcAg 
immunohistochemical staining 48 hours post HBV challenge. 
As shown in Figure 4B, a considerable amount of HBcAg-
positive hepatocytes around blood vessels (the binucleated cells 
as enlarged in Figure 4B (d) inset) could be identified in the 
group coexpressing FTL and SCCA1. The liver tissues of the 
other three groups were also extensively investigated, however, 
no obvious positive staining was detected. The data in Figure 4B 
strongly suggest that human SCCA1 or human FTL alone 
was not sufficient to introduce HBV viral particles into mouse 
liver cells. Only when both of them were expressed in mouse 
hepatocytes could the HBV viral particles enter mouse hepato-
cytes. Since the plasmid DNA introduced into hepatocytes by 
hydrodynamic injection was principally concentrated around 
liver blood vessels,31 this distribution of positive cells may 
resemble the situation of first round infection of viral particles 
introduced by tail-vein injection of patient serum.
Discussion
HBV infection targets hepatocytes in the liver. Interaction of 
viral proteins and host receptors was believed to be involved 
in HBV tropism. Characterization of HBV receptor proteins 
of human hepatocytes has received substantial attention 
over many years. Many proteins have been reported to show 
binding activities to the viral surface protein HBsAg, includ-
ing human interleukin-6,17 human immunoglobulin A,18 an 
80 kDa protein,19 asialoglycoprotein receptor,10,11 and poly 
human serum albumin.8,20 However, convincing evidence 
was absent to prove involvement of those candidates in HBV 
attachment and entry into human hepatocytes. Previous 
studies have revealed the possibility of the membrane 
protein SCCA1 as a receptor of HBV, since it was purified 
by affinity chromatography using a tetravalent derivative 
of the preS1 (21–47) sequence.12 Expression of SCCA1 in 
mouse liver could extend the retention of HBV in mouse 
liver.21 We started to search for a second factor or factors 
other than SCCA1 because of the different affinity of 
HBV to HepG2 and CHO cells which were overexpressing 
SCCA1. FTL was also the only target which was positive 
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for both baits (preS and SCCA1) in our extensive screening. 
Several lines of evidence supported our hypothesis that FTL 
could be a cofactor for SCCA1 in HBV cellular attach-
ment: (1) both preS and SCCA1 are bound to FTL in vitro 
and in HepG2 cells, (2) preS and SCCA1 bind to distinct 
subregions of FTL, (3) coexpression of FTL and SCCA1 
enhanced HBV infection in human HepG2 and CHO cells, 
and (4) coexpression of FTL and SCCA1 in mice liver via 
hydrodynamic injection enhanced HBV attachment and 
replication in hepatocytes.
Unlike preS1 domain, preS2 domain seems dispens-
able for HBV infectivity,22 but in another study, Le Seyec23 
Figure 4 Coexpression of human SCCA1 and FTL in mouse liver enhances HBV replication. Plasmids pcDNA3.1 (column 1 in A; a in B), pcDNA3.1-SCCA1 (column 2 in A; 
b in B), pcDNA3.1-FTL (column 3 in A; c in B), or both of pcDNA3.1-SCCA1 and pcDNA3.1-FTL (column 4 in A; d in B) were introduced into mouse liver via hydrodynamic 
injection through tail vein. (A) Serum level of HBsAg determined 24 hours post virus challenge. (B) Immunohistochemical staining of HBcAg 48 hours post virus challenge.
Abbreviations: SCCA1, squamous cell carcinoma antigen 1; FTL, ferritin light chain; HBV, hepatitis B virus; HBsAg, hepatitis B virus surface protein antigens; HBcAg, hepatitis B 
virus core protein antigens.
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mouse and bovine FTL. Similarly, the glutamine residue at 
position 26 of human FTL is replaced by arginine in mouse 
and bovine FTL. The two mutations (S19R and Q26R) intro-
duce two positive charges, and this may directly modulate 
the protein–protein interaction of FTL to preS2, since the 
side chains of the two amino acids is located at the surface 
of helix A as predicted by molecular modeling (Figure 5B). 
The differential surface change may explain host restriction 
of HBV infection, and no interference of bovine or mouse 
FTL in our cell culture and mouse studies.
Coreceptors are widely involved in viral infection. 
Besides the well-known coreceptors CCR5 or CXCR4 that 
are required for HIV attachment to CD4+ cells,27,28 studies 
on cellular receptors of hepatitis C virus,29 Epstein–Barr 
virus,30 and other viruses have implicated coreceptors in 
viral infection. Advantages for viruses to have coreceptors 
for cellular infection rather than a single receptor protein 
may include avoiding loss of infectiveness due to host gene 
mutations, and increasing specificity of host cell types.
This work is the first case reporting a successful in vivo 
infection of HBV in mouse hepatocytes with the help of 
hydrodynamic injection. However, solid evidence is required 
to confirm the role of FTL as the second receptor for HBV 
infection. One possible approach may be preparation of trans-
genic mice coexpressing human SCCA1 and FTL genes so 
that the susceptibility to HBV infection of the transgenic mice 
could be investigated. Nevertheless, our study may shed new 
light on the nature of HBV infection and may provide new 
targets for drug development to prevent HBV infection and for 
A
B
Figure 5 (A) Comparison of the FTL N-terminal amino acids sequence of human, mouse and bovine. (B) Illustration of the position of S19R and Q26R on 3D structure.
Abbreviation: FTL, ferritin light chain.
demonstrated that only the first 5 amino acids at the 
N-terminal of the preS2 domain is essential for virion export 
and the preS2 domain could still contribute to virus entry.24 
In our results, the binding motif of preS2 is located right in 
the N-terminal 11 amino acids.
Ferritin is the major iron storage protein of mammals with 
a molecular weight of 450 kDa, which consists of 24 heavy 
or light chains and is expressed in various tissues. Ferritin in 
liver and serum contains only 24 light chains.25 Despite the 
only 53% sequence homology, human FTL and ferritin heavy 
chain (FTH) share an almost identical tertiary structure consist-
ing of five helices.26 It is not clear how ferritin is secreted into 
serum since neither FTH nor FTL have signal peptides which 
are essential for secretory proteins. One possibility is that the 
special tertiary structures of FTL and FTH make them easy to 
fuse with the cell membrane and pass through it so that ferritin 
is assembled outside the cells. Another possibility is that it is 
the characteristic global structure of ferritin that makes it easy 
to pass through the cell membrane. In either case, FTL should 
be able to fuse with cell membranes and hence directly interact 
with membrane protein SCCA1 on HepG2 cells.
The deletion experiments revealed that helix A is the 
binding site of preS while the other four helices (B–E) are 
required for maintaining the correct three-dimensional struc-
ture needed for binding of SCCA1. We compared the FTL 
amino acid sequences of human, bovine, and mouse, and 
found that there are two key amino acid mutations. As shown 
in Figure 5A, the serine amino acid residue at position 19 
of the N-terminus of human FTL is replaced by arginine in 
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therapeutic use. Realistically, infusion of excessive FTL may 
block HBV infection since expression of FTL in HepG2 cells 
could reduce the absorption of HBV significantly.
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